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Objective: to investigate the efficacy of quinupristin/dalfopristin in the prevention of prosthetic graft infection in a
rat subcutaneous pouch model.
Methods: graft infections were established in the subcutaneous tissue of 140 male Wistar rats by implantation of Dacron
prostheses followed by topical inoculation with Staphylococcus epidermidis with intermediate resistance to glycopep-
tides. The study included one group without contamination, one contaminated group without prophylaxis, one contami-
nated group that received 50 mg/l quinupristin/dalfopristin-soaked graft, one contaminated group that received 10 mg/kg
intraperitoneal levofloxacin, one contaminated group that received 3 mg/kg intraperitoneal doxycycline, and two contami-
nated groups that received 50 mg/l quinupristin/dalfopristin-soaked plus 10 mg/kg intraperitoneal levofloxacin or 3 mg/kg
intraperitoneal doxycycline. Each group included 20 animals. The grafts were removed after 7 days and evaluated by
quantitative culture.
Results: quinupristin/dalfopristin showed a significantly higher efficacy than levofloxacin and doxycycline, even though
quantitative graft cultures for rats that received only quinupristin/dalfopristin-soaked graft showed bacterial growth.
Otherwise, the efficacy of levofloxacin was similar to that of doxycycline. Only the group treated with quinupristin/
dalfopristin combined with levofloxacin or doxycycline showed no evidence of staphylococcal infection.
Conclusions: quinupristin/dalfopristin as adjunctive topical antibiotic prophylaxis can be useful for the prevention
of vascular graft infections caused by staphylococcal strains with high levels of resistance.
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Gram-positive infections are causing more serious
infections than ever before in surgical patients,
who are increasingly aged, ill, and debilitated.1±3
Coagulase-negative staphylococci, chiefly the skin
commensal Staphylococcus epidermidis, are among the
most common pathogens that cause graft infection,
a dread severe complication of vascular reconstruc-
tions frequently resulting in loss of organ function,
limb, and life.4±6
Effective strategies for the prevention of pros-
thetic infection vary from device to device and arePlease address all correspondence to: A. Giacometti, Clinica delle
Malattie Infettive, c/o Ospedale Regionale, via Conca, 60020
Ancona, Italy.
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before, during and after operation. The mainstay of
prophylaxis are asepsis and perioperative administra-
tion of systemic antibiotics.1,7±9 The choice of anti-
biotic and length of treatment are controversial,
although first and second generation cephalosporins
have been the most commonly used drugs.10,11 How-
ever, the antibiotic used should be guided by local
bacterial prevalence and sensitivities, remembering
that most infections are caused by staphylococci.
Moreover, as adjunctive prophylaxis in the case of
vascular grafts, antimicrobials bound in high concen-
trations to prosthetic grafts have been proposed.12±16
Particularly, the efficacy of rifampin bonding on
vascular graft to prevent prosthetic infections was
demonstrated since 1990.17±19 Nevertheless, the
use of broad-spectrum antibiotics can select for thel rights reserved.
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resistant strains of Staphylococcus aureus (MRSA) and
Staphylococcus epidermidis (MRSE) emerged during the
1970s and, successively in the 1980s, it has been
described the emergence of vancomycin resistance in
coagulase-negative staphylococci (CNS).20±25
To treat infections caused by these multidrug-
resistant organisms and to reduce the increasing selec-
tion pressure by glycopeptides on Gram-positive
pathogens in hospitals new antibiotics are needed.
One of these compounds is the new semisynthetic
injectable streptogramin quinupristin-dalfopristin
(Q-D). It is composed of two synergistic pristinamycin
derivatives, quinupristin, a peptide macrolactone clas-
sified as a type B streptogramin, and dalfopristin, a
polyunsaturated macrolactone classified as a type A
streptogramin in a 30 : 70 ratio. Q-D inhibits protein
synthesis by irreversibly binding to the 50S ribosomal
subunit. It has a focused spectrum of in vitro activity
against Gram-positive cocci, including methicillin-
resistant isolates of staphylococci, streptococci, and
Enterococcus faecium.26,27
Levofloxacin, a fluoroquinolone with somewhat
enhanced activity against Gram-positive cocci, is
the L-stereoisomer of ofloxacin, which is a racemic
mixture that contains equal parts of the L- and
D-stereoisomers. It is more active than ofloxacin or
ciprofloxacin against streptococci and staphylococci,
and higher peak concentrations in serum can be
achieved with the recommended doses.28
Doxycycline is a long-acting tetracycline that acts
against susceptible organisms by inhibiting protein
synthesis. It enter bacteria by an energy-dependent
process and bind reversibly to the 30S ribosomal sub-
units of the bacteria. All tetracyclines have similar
antimicrobial spectra, with activity against many
Gram-positive aerobic cocci, including staphylococci
and streptococci.29
In this study we used one strain of S. epidermidis
with intermediate resistance to vancomycin to inves-
tigate the in vivo efficacy of Q-D, alone and in
combination with doxycycline and levofloxacin,
in preventing prosthesis infection in a rat model.
Materials and Methods
Organisms
The strain of S. epidermidis with intermediate resist-
ance to vancomycin used in this study was isolated
from a clinical specimen submitted for routine bac-
teriological investigation to the Institute of Infectious
Diseases and Public Health, University of Ancona,Italy. This isolate was described using the acronym
VISE (vancomycin-intermediate S. epidermidis).
Drugs
Q-D was obtained from Aventis Pharma, Centre de
Recherches, Vitry-Alfortville, France. Vancomycin,
cefazolin, cefamandole, rifampin and doxycycline (all
from Sigma-Aldrich, Milan, Italy) and levofloxacin
(GlaxoSmithKline, Verona, Italy) were diluted in
accordance with manufacturers' recommendations.
Solutions of drugs were made fresh on the day of
assay or stored at ÿ80 C in the dark for short periods.
Antimicrobial susceptibility testing
The antimicrobial susceptibilities of the strain to the
above mentioned drugs were determined by the broth
microdilution method described by the National
Committee for Clinical Laboratory Standards,
NCCLS. In addition, the strain was tested for sus-
ceptibility to vancomycin by the NCCLS reference
disk diffusion method using 30 mg vancomycin
discs.30,31 Experiments were performed in triplicate.
In vivo rat model
Graft infections were established in the subcutaneous
tissue of 140 male Wistar rats by implantation of
Dacron prostheses followed by topical inoculation of
the VISE strain. The study included one group with-
out contamination, one contaminated group without
prophylaxis, one contaminated group that received
50 mg/l Q-D-soaked graft, one contaminated group
that received 10 mg/kg intraperitoneal levofloxacin,
one contaminated group that received 3 mg/kg intra-
peritoneal doxycycline, and two contaminated groups
that received 50 mg/l Q-D-soaked plus 10 mg/kg
intraperitoneal levofloxacin or 3 mg/kg intraperito-
neal doxycycline. Each group included 20 animals.
Rats were anaesthetised with ether, the hair on
the back was shaved and the skin cleaned with 10%
povidone±iodine solution. One subcutaneous pocket
was made on each side of the median line by a 1.5 cm
incision. Aseptically, 1 cm2 sterile collagen-sealed
double velour knitted polyethylene terephthalate
(Dacron) grafts (AlbograftTM, Sorin Biomedica Cardio,
Saluggia VC, Italy) were implanted into the pockets.
Before implantation, the Dacron graft segments were
impregnated with Q-D at concentrations of 50 mg/l.
Bonding of the compound was obtained immediatelyEur J Vasc Endovasc Surg Vol 24, September 2002
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a sterile solution of the above-mentioned agent. The
pockets were closed by means of skin clips and
physiological solution (1 ml) containing the VISE
strain at a concentration of 2 107 CFU/ml was inocu-
lated on to the graft surface using a tuberculin syringe
to create a subcutaneous fluid-filled pocket. The
animals were returned to individual cages and
thoroughly examined daily. All grafts were explanted
at 7 days following implantation. This study was
approved by the Animal Research Ethics Committee
of the I.N.R.C.A. I.R.R.C.S., University of Ancona.
Assessment of the infection
The explanted grafts were placed in sterile tubes,
washed in sterile saline solution, placed in tubes con-
taining 10 ml of phosphate-buffered saline solution
and sonicated for 5 min to remove the adherent bac-
teria from the grafts. Quantitation of viable bacteria
was performed by culturing serial 10-fold dilutions
(0.1 ml) of the bacterial suspension on blood agar
plates. All plates were incubated at 37 C for 48 h and
evaluated for the presence of the VISE strain. The
organisms were quantificated by counting the number
of CFU per plate. The limit of detection for this
method was approximately 10 CFU/ml.
Statistical analysis
MIC values are presented as the mode of three
separate experiments. Quantitative culture results
regarding the in vivo studies were presented as
mean standard deviation of the mean. Comparisons
of the results were performed by Kruskal±Wallis
test. Significance was accepted when the p value
was 0.05.Table 1. Quantitative microbiologic results of the in vi
Group a Graft-soaked
drug b
In
p
Uncontaminated group ± ±
Contaminated group ± ±
Group 1 Q-D ±
Group 2 ± L
Group 3 ± D
Group 4 Q-D L
Group 5 Q-D D
a Each group was formed by 20 animals.
b The Dacron graft segments were impregnated 50 mg/l
c Levofloxacin 10 mg/kg; doxycycline 3 mg/kg.
d Statistically significant when compared with contamin
e Statistically significant when compared with groups 2
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In vitro data
According to the broth microdilution method recom-
mended by the NCCLS the isolate confirmed its
intermediate resistance to vancomycin. Actually,
vancomycin exhibited MICs of 8 g/ml and zone
sizes of 11 mm by the disc diffusion test. Q-D, cefazo-
lin, cefamandole, rifampin, doxycycline, and levo-
floxacin showed MICs of 128, 64, 32, 128, and
32 g/ml, respectively.
In vivo data
All 20 rats included in the untreated control group
demonstrated evidence of graft infection, with
quantitative culture data showing 6.0 106 3.3
106 CFU/ml while none of the animals included in
the uncontaminated control group had microbiolo-
gical evidence of graft infection. Q-D showed a
significantly higher efficacy than levofloxacin and
doxycycline (p5 0.001), even though quantitative
graft cultures for rats that received only Q-D-soaked
graft showed bacterial growth. Otherwise, intraperi-
toneal levofloxacin showed to be slightly more effect-
ive than doxycycline intraperitoneal, even though
there were not significant differences in the results
from the quantitative bacterial graft cultures for data
obtained from the two groups (p 0.12). In detail, for
the group that received Q-D-soaked graft and the
groups that received intraperitoneal levofloxacin
and doxycycline the quantitative graft cultures
showed 2.56 102+ 1.86 102, 5.86 105+ 2.06 105
and 6.76 105+ 8.96 104 CFU/ml, respectively. Only
the groups with combined treatment showed no evi-
dence of staphylococcal infection (510 CFU/ml). The
results are summarized in Table 1. Overall, there werevo experiments.
traperitoneal
reoperative drug c
Quantitative graft
culture (CFU/ml)
510.0
6.0 106 3.3 106
2.5 102 1.8 102 de
evofloxacin 5.8 105 2.0 105
oxycycline 6.7 105 8.9 104
evofloxacin 510.0 de
oxycycline 510.0 de
Quinupristin-Dalfopristin (Q-D).
ated control group (p5 0.001).
and 3 (p5 0.001).
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from the contaminated control group were compared
with those obtained from the group that received Q-D-
soaked and the groups that received combined treat-
ment (p5 0.001).
Discussion
S. epidermidis and other coagulase-negative staphylo-
cocci isolated from hospitalised patients were often
considered contaminants. Now, they are among the
leading causes of nosocomial infection S. epidermidis
is the most important pathogen causing infections
related to implanted foreign bodies. It is well known
that vascular surgery patient's own endogenous flora
is the most likely source of infection and that it can
occur by contamination with only a few bacteria dur-
ing the implantation of the device.4 Most important in
the pathogenesis of foreign body-associated infection
due to staphylococci is the colonisation of the polymer
surface. Bacteria that adhere to implanted medical
devices can encase themselves in a hydrated matrix
of polysaccharide and protein, and form a slimy
layer known as a biofilm. Formation of these sessile
communities and their inherent resistance to anti-
microbial agents are the root of many persistent
and chronic bacterial infections.6 In addition, the
use of a broad-spectrum antibiotics selects for the
emergence of resistant pathogens. Potential sites of
nosocomial Gram-positive infections include the
urinary tract, intravascular loci, lung and pleural
space, peritoneal cavity, and finally surgical sites
including prosthetic devices. The emergence of
methicillin-resistant staphylococci and glycopeptide-
intermediate andglycopeptide-resistant Gram-positive
cocci created a pressing need for effective alternative
antibiotics.17±20,25,32 In the recent years, the new strep-
togramin combination Q-D demonstrated a selective
spectrum of antibacterial activity, primarily against
Gram-positive aerobic bacteria. Therefore, it has
been assessed mainly in emergency-use protocols, in
hospitalised patients with skin and skin-structure
infections and in patients with glycopeptide-resistant
Gram-positive infections.20
It is well known that the success of surgical prophy-
laxis can be dependent on the pharmacokinetics of
antibiotic tissue penetrance with its maintenance of
adequate tissue levels for the duration of the vascular
surgical procedure. As adjunctive prophylaxis in the
case of vascular grafts, antimicrobials bound in high
concentrations to prosthetic grafts gave encouraging
results. In particular several studies demonstrated theefficacy of rifampin bonding to prevent vascular graft
infections.12±19
Since Q-D has been introduced into clinical practice
as a consequence of the emergence of multidrug-
resistant staphylococci, we investigated its ability to
prevent graft infections due to a strain with intermedi-
ate resistance to vancomycin. Our results were similar
to those reported by the above-mentioned studies,
who found that the use of antibiotic-soaked Dacron
graft alone or with parenteral administration of
other drugs can result in significant bacterial growth
inhibition even though high concentrations of organ-
isms are topically inoculated on the Dacron pros-
theses. However, it is important to note that only
Q-D combined with intraperitoneal antibiotics was
able to inhibit completely the growth of the resistant
strains.
The clinical experience clearly shows that the pre-
vention of serious staphylococcal infections, such as
vascular graft infection, typically requires the use of
antimicrobial agents with bactericidal activity. For this
reason, a prevention through an effective antibiotic
prophylaxis plays an important role on the control of
these infections with a great impact on patient mor-
tality and the cost-effectiveness of hospital care. In
view of our results, further studies are needed to
investigate the potential usefulness of Q-D in peri-
operative chemoprophylaxis of prosthetic surgery.
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